Live Chat

交易 BioNTech BNTX

BioNTech 实时图表

金融票据基础知识

Weekly Search
Weekly
Daily
日期 关闭 更改 更改(%): 开盘价

最新新闻

Global finance
Neil Wilson 2024 Nov 14, 17:00

Fed Hints at Tight Policy Amid Global Economic Uncertainty

Fed
Frances Wang 2024 Nov 14, 16:00

Dogecoin surges after Elon Musk issues crypto endorsement

Cryptocurrencies
Nvidia Blackwell AI Chips
Neil Wilson 2024 Nov 14, 16:00

Week ahead: Tech rally hinges on Nvidia earnings

Forex Indices
Frances Wang 2024 Nov 14, 16:00

Stock Market Today: Indexes Drop as Fed Rate Cuts are still underway

Fed Stocks
Frances Wang 2024 Nov 14, 16:00

What's Going On With Amazon Stock today? Is AMZN expected to rise?

Stocks AMZN
Dogecoin surges
Neil Wilson 2024 Nov 13, 17:00

Dogecoin surges as Trump unveils new government efficiency initiative with Musk andRamaswamy

Cryptocurrencies
Frances Wang 2024 Nov 13, 16:00

Japanese Yen to USD: Yen drops to fresh multi-month low against USD

Forex
Frances Wang 2024 Nov 13, 16:00

Asia markets today: Nikkei 225 up 0.18%, Hang Seng Index falls by 197 points

Indices

信息

点差

0.7754

点差(%)

0.7844 %

杠杆

1:10

隔夜利息(买入)

-0.0597 %

隔夜利息(卖出)

-0.0292 %

币种

USD

交易时间

市场开放

星期五

14:31 - 20:59

星期一

14:31-20:59

星期二

14:31-20:59

星期三

14:31-20:59

星期四

14:31-20:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

24827473920

在外流通股份

239740000

财报日(下一)

0000-00-00

股息收益率

2022-06-17

除息日

2022-06-02

远期年度股息率

0

远期年股息率

0

每股收益

-1.92

详细了解此金融票据

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

相关金融票据

资产
出售
买入
更改(%):
相关金融票据
Trustpilot
Live Chat